OKYO PHARMA LTD Financials
This page shows OKYO PHARMA LTD (OKYO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing inflows, not operating receipts, are carrying a business with persistent negative equity and tightening liquidity.
In FY2023, operating cash flow of-$7.7M was accompanied by financing inflow of$9.3M , indicating that operations were funded through financing rather than internally generated cash. FY2025 repeats that pattern, with operating cash flow of-$1.8M alongside financing inflow of$2.7M , while equity remained negative; the balance sheet is therefore being supported by capital raised or arranged outside operations.
The current ratio fell from 3.2x in FY2022 to 0.7x in FY2023, shifting from reported short-term coverage to pressure from current obligations. By FY2025, current liabilities of
In FY2025, the net loss of
Financial Health Signals
OKYO PHARMA LTD does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
OKYO PHARMA LTD reported a net loss of $4.7M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
OKYO PHARMA LTD reported -$4.7M in net income in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
OKYO PHARMA LTD recorded an outflow of $1.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
OKYO PHARMA LTD held $1.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
OKYO PHARMA LTD invested $1K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
OKYO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).
OKYO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|---|
| Total Assets | $3.7M+138.6% | $1.5M-70.4% | $5.2M+21.0% | $4.3M-39.4% | $7.1M |
| Current Assets | $3.7M+139.0% | $1.5M-70.4% | $5.2M+21.0% | $4.3M-38.5% | $7.0M |
| Cash & Equivalents | $1.6M+88.8% | $827K-79.6% | $4.0M+49.8% | $2.7M-60.8% | $6.9M |
| Accounts Receivable | N/A | N/A | $592K-27.2% | $813K+1774.5% | $43K |
| Total Liabilities | $9.2M+24.3% | $7.4M+2.3% | $7.3M+436.3% | $1.4M-23.6% | $1.8M |
| Current Liabilities | $9.2M+24.3% | $7.4M+2.3% | $7.3M+436.3% | $1.4M-20.7% | $1.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $65K |
| Total Equity | -$5.5M+5.6% | -$5.9M-186.4% | -$2.1M-169.7% | $2.9M-44.6% | $5.3M |
| Retained Earnings | -$143.0M-0.4% | -$142.5M-13.4% | -$125.7M-11.8% | -$112.4M-6.1% | -$106.0M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
OKYO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
OKYO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'25 | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|---|
| Current Ratio | 0.40+0.2x | 0.21-0.5x | 0.72-2.5x | 3.17-0.9x | 4.09 |
| Debt-to-Equity | N/A | N/A | N/A | 0.46+0.4x | 0.01 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.
Note: Shareholder equity is negative (-$5.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.40), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where OKYO PHARMA LTD Ranks
Frequently Asked Questions
Is OKYO PHARMA LTD profitable?
No, OKYO PHARMA LTD (OKYO) reported a net income of -$4.7M in fiscal year 2025.
What is OKYO PHARMA LTD's free cash flow?
OKYO PHARMA LTD (OKYO) recorded an outflow of $1.8M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OKYO PHARMA LTD's operating cash flow?
OKYO PHARMA LTD (OKYO) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are OKYO PHARMA LTD's total assets?
OKYO PHARMA LTD (OKYO) had $3.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OKYO PHARMA LTD's capital expenditures?
OKYO PHARMA LTD (OKYO) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is OKYO PHARMA LTD's current ratio?
OKYO PHARMA LTD (OKYO) had a current ratio of 0.40 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is OKYO PHARMA LTD's return on assets (ROA)?
OKYO PHARMA LTD (OKYO) had a return on assets of -128.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is OKYO PHARMA LTD's debt-to-equity ratio negative or not reported?
OKYO PHARMA LTD (OKYO) has negative shareholder equity of -$5.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Are OKYO PHARMA LTD's earnings high quality?
OKYO PHARMA LTD (OKYO) reported a net loss of $4.7M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.